TY - JOUR
T1 - The potential effect of improved provision of rabies post-exposure prophylaxis in Gavi-eligible countries
T2 - a modelling study
AU - WHO Rabies Modelling Consortium
AU - Hampson, Katie
AU - Ventura, Francesco
AU - Steenson, Rachel
AU - Mancy, Rebecca
AU - Trotter, Caroline
AU - Cooper, Laura
AU - Abela-Ridder, Bernadette
AU - Knopf, Lea
AU - Ringenier, Moniek
AU - Tenzin, Tenzin
AU - Ly, Sowath
AU - Tarantola, Arnaud
AU - Moyengar, Ronelngar
AU - Oussiguéré, Assandi
AU - Bonfoh, Bassirou
AU - Narayana, DH Ashwath
AU - Sudarshan, Mysore Kalappa
AU - Muturi, Matthew
AU - Mwatondo, Athman
AU - Wambura, Gati
AU - Andriamandimby, Soa Fy
AU - Baril, Laurence
AU - Edosoa, Glenn T.
AU - Traoré, Abdallah
AU - Jayme, Sarah
AU - Kotzé, Johann
AU - Gunesekera, Amila
AU - Chitnis, Nakul
AU - Hattendorf, Jan
AU - Laager, Mirjam
AU - Lechenne, Monique
AU - Zinsstag, Jakob
AU - Changalucha, Joel
AU - Mtema, Zac
AU - Lugelo, Ahmed
AU - Lushasi, Kennedy
AU - Yurachai, Onphirul
AU - Metcalf, Charlotte Jessica E.
AU - Rajeev, Malavika
AU - Blanton, Jesse
AU - Costa, Galileu Barbosa
AU - Sreenivasan, Nandini
AU - Wallace, Ryan
AU - Briggs, Deborah
AU - Taylor, Louise
AU - Thumbi, Samuel M.
AU - Huong, Nguyen Thi Thanh
N1 - Publisher Copyright:
© 2019 World Health Organization
PY - 2019/1
Y1 - 2019/1
N2 - Background: Tens of thousands of people die from dog-mediated rabies annually. Deaths can be prevented through post-exposure prophylaxis for people who have been bitten, and the disease eliminated through dog vaccination. Current post-exposure prophylaxis use saves many lives, but availability remains poor in many rabies-endemic countries due to high costs, poor access, and supply. Methods: We developed epidemiological and economic models to investigate the effect of an investment in post-exposure prophylaxis by Gavi, the Vaccine Alliance. We modelled post-exposure prophylaxis use according to the status quo, with improved access using WHO-recommended intradermal vaccination, with and without rabies immunoglobulin, and with and without dog vaccination. We took the health provider perspective, including only direct costs. Findings: We predict more than 1 million deaths will occur in the 67 rabies-endemic countries considered from 2020 to 2035, under the status quo. Current post-exposure prophylaxis use prevents approximately 56 000 deaths annually. Expanded access to, and free provision of, post-exposure prophylaxis would prevent an additional 489 000 deaths between 2020 and 2035. Under this switch to efficient intradermal post-exposure prophylaxis regimens, total projected vaccine needs remain similar (about 73 million vials) yet 17·4 million more people are vaccinated, making this an extremely cost-effective method, with costs of US$635 per death averted and $33 per disability-adjusted life-years averted. Scaling up dog vaccination programmes could eliminate dog-mediated rabies over this time period; improved post-exposure prophylaxis access remains cost-effective under this scenario, especially in combination with patient risk assessments to reduce unnecessary post-exposure prophylaxis use. Interpretation: Investing in post-exposure vaccines would be an extremely cost-effective intervention that could substantially reduce disease burden and catalyse dog vaccination efforts to eliminate dog-mediated rabies. Funding: World Health Organization.
AB - Background: Tens of thousands of people die from dog-mediated rabies annually. Deaths can be prevented through post-exposure prophylaxis for people who have been bitten, and the disease eliminated through dog vaccination. Current post-exposure prophylaxis use saves many lives, but availability remains poor in many rabies-endemic countries due to high costs, poor access, and supply. Methods: We developed epidemiological and economic models to investigate the effect of an investment in post-exposure prophylaxis by Gavi, the Vaccine Alliance. We modelled post-exposure prophylaxis use according to the status quo, with improved access using WHO-recommended intradermal vaccination, with and without rabies immunoglobulin, and with and without dog vaccination. We took the health provider perspective, including only direct costs. Findings: We predict more than 1 million deaths will occur in the 67 rabies-endemic countries considered from 2020 to 2035, under the status quo. Current post-exposure prophylaxis use prevents approximately 56 000 deaths annually. Expanded access to, and free provision of, post-exposure prophylaxis would prevent an additional 489 000 deaths between 2020 and 2035. Under this switch to efficient intradermal post-exposure prophylaxis regimens, total projected vaccine needs remain similar (about 73 million vials) yet 17·4 million more people are vaccinated, making this an extremely cost-effective method, with costs of US$635 per death averted and $33 per disability-adjusted life-years averted. Scaling up dog vaccination programmes could eliminate dog-mediated rabies over this time period; improved post-exposure prophylaxis access remains cost-effective under this scenario, especially in combination with patient risk assessments to reduce unnecessary post-exposure prophylaxis use. Interpretation: Investing in post-exposure vaccines would be an extremely cost-effective intervention that could substantially reduce disease burden and catalyse dog vaccination efforts to eliminate dog-mediated rabies. Funding: World Health Organization.
UR - http://www.scopus.com/inward/record.url?scp=85059241333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059241333&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(18)30512-7
DO - 10.1016/S1473-3099(18)30512-7
M3 - Article
C2 - 30472178
AN - SCOPUS:85059241333
SN - 1473-3099
VL - 19
SP - 102
EP - 111
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 1
ER -